KDR and lung cancer: Conversely, in unselected patients in human disease, VEGFR inhibitors as single agents show only modest activity in NSCLC (39–41) but greater activity in other tumour settings (5,7,8), perhaps suggesting that non-anti-angiogenic modes of action may contribute more significantly to activity in lung cancer in certain patients in the clinic.